Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab

Figure 1

Changes in BMD over 1 year. Changes over 1 year in bone mineral density (BMD), for methotrexate (control) and infliximab groups, are represented in percentages at (a) the femoral neck and (b) lumbar spine. For the infliximab group, changes in BMD are also separated according to the clinical response, defined by an improvement of at least 1.2 in Disease Activity Score (DAS)28 score over 1 year. NS, not significant.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us